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changes did not correlate with markers of levodopa toxicity 
such as vitamin B12 deficiency. Our findings suggest that 
loss of peripheral nerve fibers is an intrinsic feature of PD 
and that peripheral nerve changes may reflect the two types 
of central alpha-synuclein-related PD pathology, namely 
neuronal death and axonal degeneration. Detection of phos-
phorylated alpha-synuclein in dermal nerve fibers might be 
a useful diagnostic test for PD with high specificity but low 
sensitivity.
Keywords Parkinson’s disease · Peripheral neuropathy · 
Alpha-synuclein · Skin biopsy · Intraepidermal nerve fiber 
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Introduction
In recent years, non-motor symptoms in Parkinson’s dis-
ease (PD) have received much attention, and PD is now 
considered a multi-systemic disorder of the nervous system. 
Deposits within neurons and neurites mainly consisting of 
phosphorylated alpha-synuclein (p-alpha-synuclein) are the 
neuropathological hallmark of the disease and are supposed 
to initially occur within brain regions, such as the vagal, 
glossopharyngeal or olfactory nucleus, receiving innerva-
tion from mucosal surface areas. From there, alpha-synu-
clein deposits spread in a characteristic stage-dependent 
pattern [3]. Several studies have detected alpha-synuclein 
deposits within structures of the peripheral nervous system 
(PNS) like dermal nerve fibers, pharyngeal nerves, nerves 
of the submandibular and minor salivary glands and nerves 
and ganglia of the enteric nervous system [1, 2, 8, 15, 20, 
24, 31, 38–40]. PD patients also have a reduced density of 
small intraepidermal nerve fibers and diminished innerva-
tion of sweat gland and erector pili muscles [8, 40, 58]. 
Abstract The deposition of alpha-synuclein in the brain, 
the neuropathological hallmark of Parkinson’s disease 
(PD), follows a distinct anatomical and temporal sequence. 
This study aimed to characterize alpha-synuclein deposi-
tion in cutaneous nerves from patients with PD. We further 
strived to explore whether peripheral nerve involvement is 
intrinsic to PD and reflective of known features of brain 
pathology, which could render it a useful tool for pathoge-
netic studies and pre-mortem histological diagnosis of PD. 
We obtained skin biopsies from the distal and proximal leg, 
back and finger of 31 PD patients and 35 controls and quan-
tified the colocalization of phosphorylated alpha-synuclein 
in somatosensory and autonomic nerve fibers and the pat-
tern of loss of different subtypes of dermal fibers. Deposits 
of phosphorylated alpha-synuclein were identified in 16/31 
PD patients but in 0/35 controls (p < 0.0001). Quantifica-
tion of nerve fibers revealed two types of peripheral neu-
rodegeneration in PD: (1) a length-dependent reduction of 
intraepidermal small nerve fibers (p < 0.05) and (2) a severe 
non-length-dependent reduction of substance P-immunore-
active intraepidermal nerve fibers (p < 0.0001). The latter 
coincided with a more pronounced proximal manifestation 
of alpha-synuclein pathology in the skin. The histological 
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Wang et al. [58] recently reported an association between 
dermal alpha-synuclein deposition and reduced autonomic 
innervation, using an alpha-synuclein-antibody that is not 
specific to the phosphorylated form. The finding of alpha-
synuclein deposits in skin nerve fibers raises the possibil-
ity of a disease-related peripheral neurodegeneration in 
PD. However, others found an association of the peripheral 
neuropathy with cumulative levodopa intake and reduced 
levels of vitamin B12 and B6, suggesting a pharmacotoxic 
cause: either due to interactions of levodopa metabolism 
with the methylation pathways of vitamin B12 or the inter-
ference of intestinal levodopa and vitamin uptake [5, 25, 
37, 43, 46, 53].
Here we hypothesized that loss of peripheral nerve fib-
ers was intrinsic to PD and that peripheral pathology might 
reflect known features of neurodegeneration within the cen-
tral nervous system, which could potentially render skin 
biopsy a useful tool for studying the pathogenesis of PD 
and establishing a reliable pre-mortem histopathological 
diagnosis of the disease.
Subjects and methods
Subjects
The study was approved by the ethical review Boards of 
the University of Würzburg and the Medical Council of 
Hessen and was conducted in accordance with the declara-
tion of Helsinki.
We included patients with idiopathic PD irrespective of 
disease stage or therapy attending the in- or outpatient ser-
vices of the Departments of Neurology of the University 
Hospital Würzburg or Paracelsus-Klinik Kassel between 
2011 and 2012. Diagnosis of PD was based on the United 
Kingdom Parkinson’s disease Society Brain Bank criteria 
[23]. Patients with other common risk factors of periph-
eral nerve dysfunction like alcoholism, chemotherapy or 
diabetes or reduced oral glucose tolerance were excluded. 
As a control group, 35 healthy volunteers without any 
sensory deficits or Parkinsonian symptoms were recruited 
from staff, relatives and patients with diseases that do not 
affect peripheral nerves (e.g. glaucoma, cataract, transient 
ischemic attacks). Controls were not allowed to have a his-
tory of diabetes, alcohol abuse, vitamin B12 deficiency, 
or any other common cause of peripheral neuropathy. 
Neurological examination was performed in all patients 
to evaluate severity of disease and to assess symptoms of 
peripheral neuropathy. Parkinsonian motor symptoms were 
quantified using the Unified Parkinson’s disease scale part 
III (UPDrS III) [17]. Disease staging was done by the 
Hoehn and Yahr scale [21]. A detailed medical history, 
including onset of disease, medication, family history and 
alcohol consumption was recorded for each patient. Non-
motor symptoms and autonomic symptoms were assessed 
by the german version of the non-motor symptom scale 
(NMSS) [51]. Calculation of the individual cumulative 
levodopa dose was based on patient interviews and medi-
cal records. laboratory tests included electrolytes, renal 
and liver function tests, whole blood and differential cell 
counts, C-reactive protein, Vitamin B12, B6, homocysteine, 
methyl malonic and folic acid levels. Demographic data of 
all participants are summarized in Table 1.
Nerve conduction studies
Antidromic neurography of the sural nerve was performed 
using surface electrodes following standard procedures 
[26]. Outcomes were categorized based on our own nor-
mative data (SNAP amplitude ≥10 µV for age <65 years, 
SNAP amplitude ≥5 µV for age ≥65 years, nerve conduc-
tion velocity >40 m/s for all ages).
Quantitative sensory testing (QST)
Quantitative sensory testing (Somedic, Hörby, Sweden) 
was performed according to a standardized protocol [45]. 
Six patients were excluded from QST due to cognitive defi-
cits or severe motor impairment, leaving QST results of 
25 patients. All subjects were tested on the dorsum of the 
foot and on the cheek of the same side while they were in a 
medication “on”-state. Patients with asymmetric symptom 
Table 1  Summary of 
demographic data of patients 
and controls
Patients with Parkinson’s  
disease (n = 31)
Controls
(n = 35)
Age (years) 65 (34–88) 59.9 (33–80)
gender M = 22, F = 9 M = 18, F = 17
Duration of disease (years) 9 (0.3–27) –
UPDrS III 36 (9–92) –
NMS-score 31 (5–107) –
Hoehn and Yahr °I = 3, °II = 9, °III = 10, °IV = 7, °V = 1 –
Cumulative levodopa dose (g) 1,514 (0–17,495) –
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distribution were examined on the more affected side. gen-
der- and age-matched controls (±2 years) were recruited 
for each patient. To compare data of patients and normal 
controls, z-scores of the log transformed raw values of each 
item were calculated [36].
Skin biopsy and immunohistochemistry
All patients and normal controls had skin punch biopsies 
of the proximal and distal leg, back (Th12) and index fin-
ger. Biopsies were taken under local anesthesia using a 
disposable punch with a diameter of 5 mm (leg and back) 
or 3 mm (index finger) as previously described [33, 56]. 
Biopsies of the proximal and distal leg of one PD patient 
and of the proximal leg of one control and the back of two 
controls could not be used because of technical problems. 
After fixation in 4 % paraformaldehyde, immunohisto-
chemical double labeling was performed on 50-µm frozen 
sections using anti-PgP9.5 (Ultraclone, Isle of Wight, UK, 
1:1,000) as an axonal marker and anti-MBP (Ultraclone, 
Isle of Wight, UK, 1:800) as a marker for myelin using the 
free-floating method with fluorescent secondary antibodies 
(Dylight 1:400, Cy3 1:100, Dianova, Hamburg, germany) 
as described previously [47]. For staining with anti-cal-
citonin gene-related peptide (CgrP, Peninsula laborato-
ries, San Carlos, California, USA, 1:500), anti-substance 
P (SP, Immunostar, Hudson, Wisconsin, USA, 1:100) and 
double immunolabeling with anti-phospho-alpha-synu-
clein (Covance, Princeton, New Jersey, USA, 1:500) and 
anti-PgP9.5 conventional non-free-floating immunohisto-
chemistry of 20 µm sections with Cy3 and Dylight as sec-
ondary antibodies was performed. Analysis of CgrP- and 
SP-positive fibers was restricted to biopsies of the distal 
and proximal leg and back. Cryo-conserved sections of 
autopsy material of the substantia nigra of patients with 
PD containing lewy bodies were postfixed with 4 % para-
formaldehyde and used as a control for p-alpha-synuclein-
staining. P-alpha-synuclein-positive cases could be found 
in each batch of staining and served as an additional 
positive control. Double staining with antibodies against 
anti-phospho-alpha-synuclein and anti-CgrP, anti-SP, 
anti-vasoactive intestinal peptide (VIP, Peninsula labora-
tories, San Carlos, California, USA, 1:500), anti-tyrosin 
hydroxylase (TH, Synaptic Systems, göttingen, germany, 
1:200) and anti-MBP was performed in all biopsies with 
alpha-synuclein deposits to determine which subtype of 
nerve fiber was affected. P-alpha-synuclein deposition was 
studied in one section of each biopsy first. Since biopsies 
from the back yielded the highest amount of nerve fibers 
immunoreactive for p-alpha-synuclein, we then performed 
serial sections of all initially negative biopsies of the back 
from patients and controls and analyzed these in a sec-
ond step. The whole biopsy was cut in 20 µm sections, 
resulting in at least 30 sections per biopsy, and every 
tenth section was double stained with anti-PgP9.5 and 
anti-p-alpha-synuclein.
Fluorescence microscopy
All sections were analyzed using a fluorescence micro-
scope (Axiophot 2, Zeiss, Oberkochen, germany) with 
an Axiocam Mrm camera (Zeiss) and SPOT software 
(Diagnostic Instruments, Inc, Sterling Heights, Michigan, 
USA). Photos were taken with a fluorescence microscope 
(Ax10, Zeiss) with CArVII-system and Visiview software 
(Visitron gmbH, Puchheim, germany). The examiner was 
blinded for the diagnosis of the biopsies. For the analysis 
of intraepidermal nerve fiber density (IeNFD) and quanti-
fication of myelinated fibers, sections immunostained with 
anti-PgP9.5 as an axonal marker and anti-MBP as a myelin 
marker were used. IeNFD was determined on three con-
secutive sections following published counting rules [30]. 
Briefly, all nerve fibers crossing the border between dermis 
and epidermis were counted and were determined as fib-
ers per epidermal length. IeNFD of CgrP- and SP-posi-
tive fibers was assessed on separate sections, following the 
same counting rules. To quantify myelinated nerve fibers, 
the number of dermal nerve bundles per mm2 containing at 
least one myelinated fiber was counted in the entire section 
excluding the subepidermal plexus as previously described 
[11]. Statistical evaluation SPSS Statistics 21 software 
(IBM, ehningen, germany) was used for statistical analy-
sis. Numerical data were compared using the non-paramet-
ric Mann–Whitney U test. Categorical data were tested by 
two-sided Fisher’s exact test. For correlation analysis we 
used Spearman’s correlation test. Analysis of covariance 
(ANCOVA) was performed to check for an effect of gender 




Thirty-one patients with PD and 35 controls gave written 
informed consent to participate in the study and to donate 
skin biopsies. There was no significant difference in age 
between patient groups and controls (Table 1). History and 
neurological examination did not reveal a peripheral neu-
ropathy in any of the patients.
Cutaneous alpha-synuclein deposits
Colocalization of anti-PgP9.5 and anti-p-alpha-synuclein 
(Fig. 1) in at least one dermal or epidermal nerve fiber, 
102 Acta Neuropathol (2014) 128:99–109
1 3
indicating p-alpha-synuclein deposition within nerves, was 
found in 16/31 patients with PD, but in none of our normal 
controls (p < 0.0001). Immunoreactivity clearly followed 
the course of the nerve fiber; single positive dots were 
not considered. The highest frequency of alpha-synuclein 
deposits was found in biopsies of the back with 11 cases 
(seven when using one section only), while there were six 
cases in the proximal leg, four in the distal leg and five in 
the finger, suggesting a decline in frequency from proxi-
mal to distal sites. Most deposits were detectable in auto-
nomic small fibers innervating blood vessels (eight cases), 
sweat glands (four) or erector pili muscles (four), but 
deposits were also present in dermal nerve bundles (two) 
and somatosensory fibers of the subepidermal plexus and 
of dermal papillae (four) and in intraepidermal nerve fib-
ers (two). P-alpha-synuclein deposits were never observed 
in myelinated fibers. Deposits within autonomic fibers were 
detected in patients of all disease stages, whereas the four 
patients with involvement of somatosensory fibers were in 
more advanced Hoehn and Yahr stages (3 and 4) and two of 
them suffered from tremor-dominant PD, which is remark-
able because only three of 31 patients had tremor-dominant 
disease. To evaluate whether p-alpha-synuclein deposits 
were more frequent in certain subtypes of nerve fibers, we 
performed double immunostaining of for p-alpha-synuclein 
with SP, CgrP, VIP and TH in all p-alpha-synuclein-posi-
tive cases (Fig. 2). P-alpha-synuclein deposition was found 
in all four subtypes of small nerve fibers but was most often 
detected in TH-positive fibers: 58 % of fibers with alpha-
synuclein aggregates were TH-positive compared to 23 % 
of SP-positive fibers, 24 % of VIP-positive fibers and only 
17 % of CgrP-immunoreactive fibers.
Morphology of p-alpha-synuclein deposits in the skin 
was identical to p-alpha-synuclein neurites in the sub-
stantia nigra of our positive controls: They formed an 
irregular line that was sometimes interrupted but clearly 
followed the course of the axon (Fig. 3). Irregularity 
was not associated with axonal swelling of nerve fibers. 
IeNFD in the proximal leg was lower in patients with 
p-alpha-synuclein deposits (p = 0.045). A reduction of 
distal IeNFD was found in 7/16 patients with p-alpha-
synuclein deposition compared to 4/15 patients without 
deposits (n.s.). P-alpha-synuclein deposits were found in 
patients of all disease stages and all ages. Neither motor 
(UPDrS III) nor non-motor symptom (NMSS) severity 
differed between patients with and without p-alpha-synu-
clein deposits.
Quantification of epidermal and dermal nerve fibers
Quantification of small intraepidermal nerve fibers 
revealed a moderate reduction of IeNFD in biopsies of 
the distal leg in PD patients compared to normal controls 
(p = 0.016; Fig. 4; Table 2, Online resource 1). This was 
not an effect of gender or age (ANCOVA: p = 0.037). 
IeNFD of the proximal leg, back and finger did not differ 
between patients and controls, suggesting length-depend-
ent small fiber involvement (i.e. only distal reduction of 
nerve fibers while proximal IeNFD is within the normal 
range) in PD (Table 2, Online resource 1). Numbers of 
myelinated fibers were also reduced in a length-depend-
ent pattern (Table 2, Online resource 1, p = 0.007). To 
better characterize the type of nerve fiber loss, we also 
quantified peptidergic fibers. SP-positive intraepidermal 
nerve fibers were severely reduced in patients in the dis-
tal and proximal leg and back (Table 2, Online resource 
1, p < 0.0001), suggesting non-length-dependent involve-
ment (i.e. distal and proximal reduction) of this small 
fiber subtype. CgrP-positive intraepidermal fibers 
showed a slight non-length-dependent reduction (Table 2, 
Online resource 1, distal leg p = 0.14, proximal leg 
p = 0.03, back p = 0.007). To better understand the rel-
evance of nerve fiber loss in skin biopsies of PD patients, 
the number of patients fulfilling published age- and gen-
der-controlled histological criteria of small fiber neu-
ropathy was determined [29]. eleven patients (36.7 %) 
showed distal IeNFD below normal values compared to 
eight controls (22.9 %).
Fig. 1  Photomicrograph of a skin biopsy of a PD patient double stained with anti-PgP9.5 and anti-p-alpha-synuclein. Note colocalization 
(arrows) of PgP9.5 (a, c) and phosphorylated alpha-synuclein (b, c) in a nerve fiber of the subepidermal plexus. Bar 50 µm
103Acta Neuropathol (2014) 128:99–109 
1 3
Fig. 2  Photomicrographs of skin biopsies of PD patients showing 
double labeling with anti-p-alpha-synuclein and anti-TH (a), anti-SP 
(b), anti-CgrP (c) and anti-VIP (d). P-alpha-synuclein deposits can 
be seen within TH-positive (a), SP-positive (b), CgrP-positive (c) 
and VIP-positive (d) fibers of the dermis. Arrows mark colocalization. 
Bars 20 µm
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QST and nerve conduction studies
Comparison of QST data of PD patients and age- and gen-
der-matched normal controls did not reveal significant differ-
ences between groups (Fig. 5). Nerve conductions studies of 
the sural nerve revealed a reduction of SNAP amplitude in 
7/29 PD patients. The median SNAP amplitude was 8.5 µV 
(2.2–36.4 µV) in patients, reflecting slight impairment of 
large nerve fibers in a subset of Parkinson’s patients (Table 2). 
SNAP amplitude was negatively correlated with duration 
of disease (Online resource 1, p = 0.008, ρ = −0.42) and 
age (p = 0.001, ρ = −0.50) and positively correlated with 
IeNFD of the distal leg (p = 0.002, ρ = 0.473). There was no 
correlation between duration of disease and age.
Vitamin levels and clinical data
Serum levels of Vitamin B12, B6, homocysteine and methyl 
malonic acid were measured to evaluate a possible role of 
hypovitaminosis in the development of peripheral neurop-
athy. reduced levels of vitamin B12 could be detected in 
2/26 PD patients, but without elevated methyl malonic acid 
levels arguing against a relevant B12 hypovitaminosis. low 
levels of vitamin B6 were found in two patients. We did not 
find any correlation between IeNFD, myelinated fibers or 
SNAP and levels of vitamin B12, homocysteine, cumulative 
levodopa intake, Hoehn and Yahr stage, UPDrS III, NMSS 
or autonomic symptoms (determined by only evaluating the 
autonomic items of the NMSS). A weak correlation was 
present between levels of vitamin B6 and distal IeNFD 
(p = 0.05, ρ = 0.37), but the low contribution to the total 
variance questions the clinical relevance of this finding.
IeNFD of PD patients was negatively correlated 
with duration of disease (Online resource 1, p = 0.005, 
ρ = −0.50). As there was no correlation between age and 
duration of disease, this correlation can be considered an 
effect of disease (partial correlation p = 0.038, ρ = −0.33).
Patients without levodopa therapy
To get further insight into whether levodopa therapy might 
be responsible for the loss of small or large nerve fibers, 
we examined a subgroup of early-stage patients (n = 6) 
who had not been exposed to levodopa yet. There was 
Fig. 3  Photomicrograph of p-alpha-synuclein immunolabeling of the substantia nigra of a PD patient (a) and of a skin biopsy of another PD 
patient (b). Morphology of p-alpha-synuclein deposits of dermal nerve fibers (b) resembles CNS lewy neurites (a). Bar 10 µm
Fig. 4  Photomicrograph of skin biopsies of the distal leg of a nor-
mal control (a) and a PD patient (b) stained with anti-PgP9.5. Note 
numerous intraepidermal nerve fibers in (a, arrows) which are rare-
fied in (b). The broken line marks the border between epidermis and 
dermis. Bar 50 µm
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no difference in IeNFD, myelinated fibers or SP-positive 
intraepidermal fibers between these subjects and patients 
who had been treated with levodopa (Online resource 1). 
P-alpha-synuclein deposits were detected in two patients 
without levodopa treatment.
Discussion
In the current study, we combined, for the first time, detec-
tion of p-alpha-synuclein, quantification of small and large 
nerve fibers in skin biopsies and assessment of vitamin 
B12 and B6 levels in PD patients. We found p-alpha-synu-
clein deposits in cutaneous nerves of 16/31 PD patients, a 
moderate length-dependent reduction of small and large 
nerve fibers and severe non-length-dependent reduction of 
SP-positive fibers. In our cohort, low levels of B vitamins 
were uncommon and we found no correlation between 
cumulative levodopa intake and loss of nerve fibers, sug-
gesting that dermal nerve fiber loss, reduction of SNAP and 
alpha-synuclein deposits were rather disease related than 
caused by a toxic effect of drug therapy. These findings are 
surprising with respect to recent studies describing a high 
prevalence of peripheral neuropathy in PD (up to 55 %) 
due to levodopa-related hypovitaminosis [5, 37, 43, 53, 54]. 
However, we did not preselect patients based on clinical 
symptoms or electrophysiological signs of peripheral nerve 
involvement unlike some previous studies, our cohort did 
not include patients with clinical symptoms of peripheral 
neuropathy, and even QST as a test for impaired small fiber 
function was normal. Therefore, comparability concerning 
vitamin levels and SNAP between our and former studies 
is limited. However, the absence of patients with relevant 
hypovitaminosis or other alternative causes of peripheral 
neuropathy in our study is important as it allows us to 
assume that involvement of peripheral nerves is intrinsic to 
PD in our patients, which is a prerequisite for analyzing the 
distinct features of PD related peripheral neuropathy.
To address the question whether pathology of the PNS 
reflects central nervous system (CNS) pathology and 
might be useful for the study of PD pathogenesis, we com-
pared our findings with known features of brain pathology 
(Table 3). Morphological appearance of p-alpha-synuclein 
Table 2  Median values and ranges of IeNFD, myelinated fibers and SNAP of patients with Parkinson’s disease and controls
MF myelinated fibers
Parkinson’s disease  
(n = 31) median (range)




IeNFD PgP 9.5 distal leg (fibers/mm) 3.56 (0.8–8.6) 6.31 (1.09–15.16) 0.016
IeNFD PgP 9.5 proximal leg (fibers/mm) 10.43 (0–21.63) 10.76 (2.49–18.61) 0.845
IeNFD PgP 9.5 back (fibers/mm) 19.83 (7.43–36.26) 24.82 (13.56–37.81) 0.084
IeNFD PgP 9.5 finger (fibers/mm) 6.13 (0.95–15.4) 7.59 (1.26–17.2) 0.131
MF distal leg (bundles/mm2) 0.34 (0–1.88) 0.68 (0–1.84) 0.007
MF proximal leg (bundles/mm2) 0.66 (0–3.65) 0.94 (0–6.37) 0.450
MF back (bundles/mm2) 1.50 (0.54–6.37) 2.06 (0.59–6.98) 0.231
MF finger (bundles/mm2) 2.97 (0.55–8.16) 3.67 (1.23–11.13) 0.393
IeNFD SP distal leg (fibers/mm) 0.43 (0–2.33) 1.14 (0–4.75) <0.0001
IeNFD SP proximal leg (fibers/mm) 1.13 (0–4.19) 1.58 (0.8–4.41) <0.0001
IeNFD SP back (fibers/mm) 5.04 (3.31–17.2) 9.57 (1.9–17.23) <0.0001
IeNFD CgrP distal leg (fibers/mm) 1.35 (0–3.81) 1.71 (0–3.13) 0.143
IeNFD CgrP proximal leg (fibers/mm) 2.36 (0–4.84) 2.81 (0.9–4.82) 0.034
IeNFD CgrP back (fibers/mm) 9.45 (6.1–15.27) 13.51 (6.7–21.27) 0.007
SNAP sural nerve (µV) 8.5 (2.2–36.4) – –
Fig. 5  Sensory profiles assessed with QST at the foot of PD patients 
compared to normal controls (zero-line). Patients did not show any 
significant difference in any QST item (CDT cold detection thresh-
old, WDT warm detection threshold, TSL thermal sensory limen, 
PHS paradoxical heat sensation, CPT cold pain threshold, HPT heat 
pain threshold, MDT mechanical detection threshold, MPT mechani-
cal pain threshold, MPS mechanical pain sensitivity, DMA dynamic 
mechanical allodynia, WUR wind-up ratio, VDT vibration detection 
threshold, PPT pressure pain threshold)
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deposits in the skin did not differ from lewy neurites 
found in sections of the substantia nigra that served as 
positive controls (Fig. 3). As described in the literature 
they appeared thread-like and sometimes presented with 
irregular varicosities [3]. regarding the type of nerve fib-
ers involved in p-alpha-synuclein pathology, deposits were 
restricted to unmyelinated fibers as reported in studies 
of the CNS [4]. They were found in VIP-, TH-, SP- and 
CgrP-positive fibers but were most frequent in TH-immu-
noreactive fibers. Alpha-synuclein deposits within SP-and 
TH-immunoreactive neurons/fibers have been reported 
in the CNS [7, 16, 28], and VIP- and TH-positive fibers 
containing alpha-synuclein aggregates were found in the 
enteric nervous system and in sympathetic ganglia [57]. 
In the brain, alpha-synuclein deposition is prevalent in the 
autonomic vagal nucleus early in the course of disease [3]. 
Correspondingly, alpha-synuclein deposits were mostly 
found in autonomic fibers in our study and by others [38, 
58]. However, in contrast to previous studies, we also show 
p-alpha-synuclein depositions in somatosensory fibers of 
the subepidermal plexus and intraepidermal fibers, giving 
evidence that alpha-synuclein pathology in the peripheral 
nervous system is not restricted to autonomic fibers. All 
four patients with somatosensory fiber involvement were 
in an advanced stage of disease. This corresponds to obser-
vations of the CNS, where alpha-synuclein spreads to sen-
sory association areas at later stages of disease finally also 
including nociceptive as well as sympathetic and parasym-
pathetic neurons of the spinal cord [3, 10]. The observa-
tion that alpha-synuclein deposition within somatosensory 
nerve fibers was more often found in patients with tremor-
dominant PD needs to be addressed in further studies.
length-dependent nerve fiber loss is generally assumed 
to be the effect of a dying-back neuropathy due to axonal 
damage, whereas non-length-dependent loss is supposed 
to be caused by loss of sensory neurons in the dorsal root 
ganglia (e.g. in ganglionitis) [18]. Predominant loss of SP-
immunoreactive intraepidermal nerve fibers in our patients 
in a non-length-dependent pattern suggests anterograde 
degeneration of SP-positive neurons in the dorsal root gan-
glia. This finding is paralleled by studies reporting loss of 
SP-containing neurons and reduction of SP levels in the 
CNS [14, 16, 19, 52]. Furthermore, SP-immunoreactive 
neurons and nerve fibers have been found to be the major 
site of alpha-synuclein deposition in colon biopsies and in 
the olfactory system early in the course of PD [49, 55].
In spite of extensive research, the exact pathomechanism 
leading to neurodegeneration in PD is still unknown. While 
detailed knowledge of the involvement of different regions 
of the brain in the course of disease has been gained in 
recent years [3], the question where the neurodegenera-
tive process begins on the cellular level is still unanswered 
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impaired axonal transport and mitochondrial dysfunction 
are discussed. Based on alpha-synuclein deposits in skin 
biopsies as well as quantification of nerve fibers, two pat-
terns of peripheral involvement could be differentiated 
in our study: IeNFD and myelinated dermal fibers were 
reduced in a length-dependent pattern, whereas SP- and 
CgrP-immunoreactive intraepidermal fibers showed a 
non-length-dependent reduction. P-alpha-synuclein depo-
sition was more frequently found at more proximal sites 
as already suggested in former studies [24, 38], reflecting 
non-length-dependent distribution as well. Those two pat-
terns might correspond to two distinct neurodegenerative 
processes currently discussed in PD brain pathology: (1) 
programmed cell death mediating soma destruction and (2) 
axonal degeneration [6]. The ongoing debate has been fos-
tered by the observed discrepancy between nigral cell loss 
and striatal dopaminergic denervation in the early stages of 
the disease.
Neuronal death is a characteristic feature of PD in the 
CNS and death of peripheral neurons of the dorsal root 
ganglia might be a correlate in the PNS resulting in non-
length-dependent peripheral nerve degeneration. So far, the 
question whether p-alpha-synuclein directly leads to neu-
ronal death is still unresolved [9]. Alpha-synuclein deposits 
in SP-containing neurons in the dorsal root ganglia or in 
proximal neurites and their subsequent degeneration might 
explain non-length-dependent loss of SP-positive intraepi-
dermal nerve fibers independent of duration of disease. 
This notion might be worth to be further investigated in 
post-mortem studies.
One of the general pathophysiological mechanisms 
resulting in length-dependent damage of peripheral nerves 
(as for example found in diabetic neuropathy) is impaired 
axonal transport. Indeed, a number of studies provide evi-
dence of impaired axonal and mitochondrial transport 
in PD in the CNS and PNS [7, 35, 50]. Altered axonal 
transport proteins have been reported in the CNS of PD 
patients [7]. Alpha-synuclein oligomers have been found 
to disturb axonal transport, and more severe Wallerian 
degeneration after nerve transection has been detected in 
axons with alpha-synuclein deposition in transgenic mice 
over-expressing alpha-synuclein, providing a possible link 
between these two suspected pathogenetic mechanisms [32, 
42, 50]. Distal alpha-synuclein deposition might induce ret-
rograde axonal degeneration, a notion which is supported 
by the observation that alpha-synuclein aggregates in car-
diac autonomic nerves are more abundant in the distal part 
of the nerve and precede aggregation in the corresponding 
sympathetic ganglia [41]. Correlation between reduced dis-
tal IeNFD and duration of disease in our patients is well in 
line with impaired axonal transport and retrograde axonal 
degeneration as it implies a slowly progressive degenera-
tion of nerve fibers with advancing disease.
P-alpha-synuclein depositions were equally found in 
patients with early and late stages of disease indicating an 
early involvement of cutaneous nerve fibers in PD. The 
observation that alpha-synuclein aggregates in cardiac 
autonomic nerves are more abundant in the distal part of 
the nerve [41] provides evidence that skin as the most dis-
tal site of the peripheral nervous system is not only easily 
accessible but might also provide an opportunity for early 
detection of alpha-synuclein pathology [20]. Here we 
found p-alpha-synuclein deposition in 16/31 PD patients, 
but not in any normal control. The number of positive cases 
is higher compared to former studies also using antibod-
ies specific against p-alpha-synuclein, probably because 
biopsies of different sites were analyzed in our study and 
our cryosections were thicker compared to other studies 
that used paraffin-embedded material [24, 38]. Wang et al. 
recently published a study analyzing alpha-synuclein depo-
sition within dermal nerve fibers using an alpha-synuclein 
antibody that is not specific to the phosphorylated form. 
They found an increase of alpha-synuclein in PD patients 
compared to controls and an association between loss of 
autonomic innervation and alpha-synuclein deposition. 
This study is of great interest as it implies that the impact 
of alpha-synuclein pathology in peripheral nerve fibers is 
larger than so far suspected. However, the use of an anti-
body that is not specific for p-alpha-synuclein requires 
complex immunohistochemical procedures with threshold 
dilution of antibodies to detect a difference in the amount 
of immunoreactivity between patients and controls and 
the cut-off value to distinguish between physiological and 
pathological conditions is not clear. Therefore, this method 
does not seem suitable for application as a biomarker in 
routine diagnostic work-up. Using conventional immuno-
histochemical staining procedures with an antibody spe-
cifically recognizing p-alpha-synuclein, we found immu-
noreactivity in 16 patients but not in any normal control, 
allowing good specificity but low sensitivity for diagnostic 
purposes. The high specificity compared to normal controls 
makes it worthwhile to discuss a diagnostic value espe-
cially at early stages when a clinical diagnosis may still be 
flawed by large uncertainties.
Our study has some limitations and further studies are 
needed to determine the exact sensitivity and specificity of 
skin biopsy as a diagnostic tool and to potentially improve 
it using higher numbers of samples or by targeted sampling, 
which would include hair follicles and sweat glands in each 
biopsy. The present study provides data of a small but well-
characterized cohort of patients with a clinical diagnosis of 
PD. When evaluating the frequency of cutaneous p-alpha-
synuclein deposition, we need to take into account that 
diagnosis of PD in our patients is based on clinical symp-
toms and sensitivity of clinical diagnosis ranges between 
70 and 90 % [22, 23, 34, 48]. Detection of alpha-synuclein 
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in skin biopsies very much depends on whether autonomic 
structures like sweat glands, vessels or erector pili muscles 
are included in the skin section. Furthermore, the inclusion 
of patients with atypical Parkinsonism would be of interest.
In summary, our data provide evidence for peripheral 
neurodegeneration as an intrinsic feature of PD. P-alpha-
synuclein deposition was found in about half of all patients 
and may be of diagnostic value, especially in early stages 
of disease. We demonstrate a strong analogy between CNS 
and PNS pathology concerning alpha-synuclein deposi-
tion, pattern of nerve fiber loss and evidence of impaired 
axonal transport, implying that skin biopsy might be an 
interesting “in vivo” method of studying the pathogen-
esis of PD. In addition to better accessibility compared to 
autopsy material, skin biopsies could be taken longitudi-
nally to assess individual disease progression, which is a 
principal shortcoming of any post-mortem study reflecting 
the terminal stage of a disease. Based on our findings we 
speculate that two independent mechanisms lead to periph-
eral neuropathy in PD, retrograde axonal degeneration due 
to impaired axonal transport and anterograde degeneration 
due to sensory neuronal cell death. Detection of phospho-
rylated alpha-synuclein in dermal nerve fibers might be a 
useful diagnostic test for PD with high specificity but low 
sensitivity.
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